ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

liposomal doxorubicin

Also written as “PLD”, “Doxorubicin Hydrochloride Liposome Injection” and “Pegylated liposomal doxorubicin”.

Its studies are mostly in Ovarian Neoplasms · Breast Neoplasms · Multiple Myeloma · Carcinoma, Ovarian Epithelial · Endometrial Neoplasms, led by 16 companies.

Drug pageLiposomal doxorubicin: every studyMany companies study it; this page follows only the 33 they lead. All 210 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 29, 200433 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnsonits history only90 open or runningphase 3since Apr 29, 2004Apr 29, 2004none ahead
Merckits history only60 open or runningphase 4since Jan 21, 2008Dec 15, 2005none ahead
CSPC Pharmaceutical Groupits history only20 open or runningphase 2since Dec 11, 2017Dec 11, 2017none ahead
Imunonits history only20 open or runningphase 2since Nov 1, 2011Jun 5, 2003none ahead
Oncotherapeuticsits history only20 open or runningphase 2since Aug 26, 2008Aug 26, 2008none ahead
TTY Biopharmits history only20 open or runningphase 2since Aug 31, 2010Aug 31, 2010none ahead
Ayana Pharmaits history only10 open or runningphase 1since Sep 17, 2018Sep 17, 2018none ahead
Azaya Therapeuticsits history only10 open or runningphase 1since Oct 19, 2012Oct 19, 2012none ahead
Baxter Healthcareits history only10 open or runningphase 1since Sep 29, 2022Sep 29, 2022none ahead
Dr. Reddy's Laboratoriesits history only10 open or runningphase 1since Sep 22, 2014Sep 22, 2014none ahead

Also a collaborator on its studies: Eisai, Novotech (Australia) Pty, Lambda Therapeutic Research, MDS Pharma Services, Essex Pharma, Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA, Ortho Biotech, Tibotec Pharmaceutical, Sequus Pharmaceuticals and Prologue Research International.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 19 studies since Jun 5, 2003.

  1. Oct 11, 2011Phase 2 study in Breast NeoplasmsTTY Biopharm · NCT01451580 · 47 enrolled · Taiwan
  2. Nov 1, 2011Phase 2 study in Colonic NeoplasmsImunon · NCT01464593 · 2 enrolled · United States
  3. Oct 19, 2012Azaya Therapeutics’ first study: phase 1 study in Ovarian NeoplasmsNew to Azaya TherapeuticsAzaya Therapeutics · NCT01715168 · 40 enrolled · United States, Canada
  4. Mar 18, 2013Phase 3 study in Carcinoma, Ovarian EpithelialJohnson & Johnson · NCT01840943 · 32 enrolled · China
  5. Mar 5, 2014Phase 1 study in NeoplasmsJohnson & Johnson · NCT02081495 · 35 enrolled · United States, Belgium, Canada and more
  6. Jul 30, 2014Phase 2 study in Multiple MyelomaOncotherapeutics · NCT02206425 · 45 enrolled · United States
  7. Aug 31, 2014Shanghai Fudan-Zhangjiang Bio-Pharmaceutical’s first study: phase 1 study in Ovarian NeoplasmsNew to Shanghai Fudan-Zhangjiang Bio-PharmaceuticalShanghai Fudan-Zhangjiang Bio-Pharmaceutical · NCT02237690 · 30 enrolled · China
  8. Sep 22, 2014Dr. Reddy's Laboratories’ first study: phase 1 study in Ovarian Epithelial Cancer RecurrentNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT02260544 · 49 enrolled · India
  9. Dec 11, 2017CSPC Pharmaceutical Group’s first study: phase 2 study in Poorly Differentiated Thyroid CarcinomaNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT03387943 · 30 enrolled · China
  10. Sep 17, 2018Ayana Pharma’s first study: phase 1 study in Ovarian NeoplasmsNew to Ayana PharmaAyana Pharma · NCT03681548 · 52 enrolled · India
  11. Jul 2, 2020No phase study in BioequivalenceCSPC Pharmaceutical Group · NCT04460820 · 32 enrolled · China
  12. Feb 10, 2022Shenzhen Kangzhe Pharmaceutical’s first study: phase 1 study in Breast NeoplasmsNew to Shenzhen Kangzhe PharmaceuticalShenzhen Kangzhe Pharmaceutical · NCT05273944 · 80 enrolled · China
  13. Sep 29, 2022Baxter Healthcare’s first study: phase 1 study in Ovarian NeoplasmsNew to Baxter HealthcareBaxter Healthcare · NCT05567601 · 36 enrolled · India
  14. Oct 18, 2023Luye Pharma Group’s first study: phase 1 study in Advanced Breast CancerNew to Luye Pharma GroupLuye Pharma Group · NCT06098599 · 48 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 33 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06098599Advanced Breast Cancer · China1CompletedLuye Pharma GroupFeb 9, 202348
NCT05567601Ovarian Neoplasms · India1CompletedBaxter HealthcareJun 21, 202436
NCT05273944Breast Neoplasms · China1UNKNOWNShenzhen Kangzhe PharmaceuticalMar 31, 202280
NCT04460820Bioequivalence · China–CompletedCSPC Pharmaceutical GroupDec 23, 201932
NCT03681548Ovarian Neoplasms · India1CompletedAyana PharmaFeb 8, 201952
NCT03387943Poorly Differentiated Thyroid Carcinoma · China2UNKNOWNCSPC Pharmaceutical GroupDec 31, 201830
NCT02260544Ovarian Epithelial Cancer Recurrent · India1CompletedDr. Reddy's LaboratoriesApr 201549
NCT02237690Ovarian Neoplasms · China1CompletedShanghai Fudan-Zhangjiang Bio-PharmaceuticalAug 201530
NCT02206425Multiple Myeloma · United States2CompletedOncotherapeuticsJan 19, 201845
NCT02081495Neoplasms · United States, Belgium, Canada and more1CompletedJohnson & JohnsonNov 201535
NCT01840943Carcinoma, Ovarian Epithelial · China3TerminatedJohnson & JohnsonMay 201432
NCT01715168Ovarian Neoplasms · United States, Canada1UNKNOWNAzaya TherapeuticsOct 201540
NCT01464593Colonic Neoplasms · United States2TerminatedImunonMay 20132
NCT01451580Breast Neoplasms · Taiwan2UNKNOWNTTY Biopharm47
NCT01210768Breast Neoplasms · Taiwan2UNKNOWNTTY BiopharmOct 31, 2022254
NCT00779285Breast Neoplasms4TerminatedMerckAug 20061
NCT00742404Multiple Myeloma · United States2UNKNOWNOncotherapeuticsJul 201035
NCT00712881Breast Neoplasms · Austria, Belgium, France and more2CompletedTeva Pharmaceutical IndustriesSep 17, 2015126
NCT00706953Multiple Myeloma2WithdrawnJohnson & JohnsonJun 20100
NCT00727961Ovarian Neoplasms4CompletedMerckJan 10, 200858
NCT00698451Ovarian Neoplasms · United States2CompletedJohnson & JohnsonOct 201054
NCT00687440Breast Neoplasms2CompletedMerckOct 24, 200827
NCT00653952Ovarian Neoplasms3TerminatedJohnson & Johnson220
NCT00610792Ovarian Neoplasms · Italy, Switzerland2WithdrawnTakedaSep 200991
NCT00604968Breast Neoplasms4TerminatedMerckOct 16, 200925
NCT00561743Multiple Myeloma2CompletedJohnson & JohnsonMay 200750
NCT00550771Breast Neoplasms2CompletedMerckAug 23, 2010181
NCT00303108Breast Neoplasms · United States2CompletedSarah Cannon Research InstituteMar 2010136
NCT00266799Breast Neoplasms3CompletedMerckSep 29, 2010210
NCT00097981Multiple Myeloma · United States3CompletedJohnson & JohnsonOct 2007225
NCT00091442Breast Neoplasms · United States, Bulgaria, Estonia and more3CompletedJohnson & JohnsonDec 2008751
NCT00082095Breast Neoplasms · United States3TerminatedJohnson & JohnsonDec 200562
NCT00061867Prostatic Neoplasms · United States1CompletedImunon

How it is read

Names in the registry

  • “PLD”, 4 entries
  • “Doxorubicin Hydrochloride Liposome Injection”, 4 entries
  • “Pegylated liposomal doxorubicin”, 3 entries
  • “Pegylated Liposomal Doxorubicin (PLD)”, 2 entries
  • “liposomal doxorubicin”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.